Amendments to the Claims

Amendments to the claims will replace all prior versions, and listings, of claims in the application.

Listing of the Claims

1. (original) A crystalline Form I of Compound I having an X-ray powder diffraction pattern comprising the following 2θ value measured using CuKα radiation: 6.3.

2. (original) A crystalline Form I of Compound I having an X-ray powder diffraction pattern comprising the following 2θ values measured using CuKα radiation: 6.3, 19.0 and 25.5.

3. (original) A crystalline Form I of Compound I of Claim 2 diffraction pattern further comprising the following 2θ values: 12.7, 22.0, 24.9 and 38.6.

4. (original) A crystalline Form I of Compound I having an X-ray powder diffraction pattern substantially similar to that set forth in Figure 1a as measured using CuKα radiation.

5. (original) A crystalline Form I of Compound I having differential scanning calorimetric curves substantially similar to those set forth in Figure 3.

6. (original) A crystalline Form I of Compound I having differential scanning calorimetric curves comprising

one endotherm at approximately 141°C and one endotherm at approximately 143°C, as measured at a ramp rate of 1°C/min.

7. (original) A crystalline Form I of Compound I having a Fourier transform infrared pattern comprising at least one of the following infrared peaks: 3462, 3285, 3106, 2770, 2752, 1991, 1882, 1747, 1696, 656, 1651, 1332, 1253 and 557.

8. (original) A crystalline Form I of Compound having a Raman peak pattern comprising at least one of the following peaks: 1739 and 1653, as measured using a spectrometer.

9. (original) A pharmaceutical composition useful for treatment of a human disease comprising crystalline Form I of Compound I and a pharmaceutically acceptable carrier.

10. (original) The composition of Claim 9, wherein a substantial percentage of Compound I is present as Form I.

11. (original) The composition of Claim 9, wherein at least 99.9% of Compound I is present as Form I.

12. (original) The composition of Claim 9, wherein at least 98% of Compound I is present as crystalline Form I.

13. (original) The composition of Claim 9, wherein at least 95% of Compound I is present as crystalline Form I.

14. (original) The composition of Claim 9, wherein at least 90% of Compound I is present as crystalline Form I.

15. (original) The composition of Claim 9, wherein at least 85% of Compound I is present as crystalline Form I.

16. (original) The composition of Claim 9, wherein at least 80% of Compound I is present as crystalline Form I.

17. (original) The composition of Claim 9, wherein the disease is depression or anxiety.

18. (original) A process for preparation of a pharmaceutical composition, comprising admixing Form I of Compound I with a pharmaceutically acceptable carrier.

19. (original) The process of Claim 18, further comprising obtaining Form I of Compound I of substantial purity.

20. (original) A method for treatment of a human disease, wherein the method comprises administering to a human subject suffering such disease a therapeutically effective amount of crystalline Form I of Compound I.

21. (original) The method of Claim 20, wherein the disease is a CNS disorder.

22. (original) The method of Claim 20, wherein the disease is anxiety or depression.

23. (original) A process of preparing of crystalline Form I of Compound I, comprising stirring a slurry of Compound I in a solvent for a period of time of no less than one hour.

24. (original) The process of Claim 23, wherein the solvent is selected from a group consisting of toluene, heptane, meta-xylene, ortho-xylene, para-xylene, isopropyl acetate, methanol, ethanol, 1-butanol, 1-octanol.

25. (original) A crystalline Form III of Compound I having an X-ray powder diffraction pattern comprising at least one of the following 2θ values measured using CuKα radiation: 6.1 and 21.2.

Claims 26-93. (canceled)